Optieum Biotechnologies is a Japanese biopharmaceutical company established in 2020. With the expertise of its founding scientists from Ehime University, Optieum has developed a novel technology called Eumbody System™ that efficiently produces single-chain antibodies (scFv) using gene editing techniques. The Eumbody System™ enables the creation of tailored antibody therapeutics for various diseases, including CAR-T cell therapy for intractable cancers as well as autoimmune disorders and infectious diseases.

Harnessing this foundational technology, Optieum relentlessly dedicates itself to drug discovery and development to deliver optimal medicines for those suffering from severe illnesses. The company aims to provide the most effective treatment options through the implementation of scFv-equipped CAR-T cells, which have shown superior therapeutic effects compared to traditional CAR-T cells. Partnering opportunities are available with Optieum for collaborative research and development.

Stay updated with the latest news on their website and connect with them through the contact form for inquiries. Optieum Biotechnologies is committed to making a significant impact in the field of biopharmaceuticals and improving patient outcomes